Memory impairment in abstinent MDMA ('Ecstasy') users

Neurology

Volumn 51, Issue 6, 1998, Pages 1532-1537

  Bolla, Karen I ^a,c   McCann, Una D ^b   Ricaurte, George A ^a  

^a DEPARTMENT OF PATHOLOGY   (United States)

^b NATIONAL INSTITUTE OF MENTAL HEALTH   (United States)

^c JOHNS HOPKINS BAYVIEW MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

3,4 METHYLENEDIOXYMETHAMPHETAMINE; 5 HYDROXYINDOLEACETIC ACID; SEROTONIN;

ADULT; AGE; AMNESIA; ARTICLE; CEREBROSPINAL FLUID LEVEL; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG ABUSE; DRUG WITHDRAWAL; EDUCATION; FEMALE; HUMAN; MALE; NEUROTOXICITY; PRIORITY JOURNAL; REGRESSION ANALYSIS; RETROSPECTIVE STUDY; SEROTONINERGIC NERVE CELL; SEX DIFFERENCE; VERBAL MEMORY;

EID: 0031648790     PISSN: 00283878     EISSN: None     Source Type: Journal    
DOI: 10.1212/WNL.51.6.1532     Document Type: Article

References (43)

1. Johnston L, Bachman J, O'Malley P. National survey results on drug use from the Monitoring the Future Study. National Institutes on Drug Abuse, 1975-1994. Vol. 2. College students and young adults. National Institutes of Health (NIH) publication no. 96-4027. Rockville, MD: NIDA, 1996.
2. Johnston L, Bachman J, O'Malley P. National survey results on drug use from the Monitoring the Future Study. National Institutes on Drug Abuse, 1975-1995. Vol. 2. College students and young adults. National Institutes of Health (NIH) publication no. 98-4140. Rockville, MD: NIDA, 1997.
3. Saunders N. Ecstasy and the dance culture. London: Nicholas Saunders, 1995.
4. Stone DM, Stahl DS, Hanson GL, Gibb JW. The effects of 3,4-methylenedioxymethamphetamine (MDMA) and 3,4-methylenedioxyamphetamine on monoaminergic systems in the rat brain. Eur J Pharmacol 1986;128:41-48.
5. Schmidt CJ. Neurotoxicity of the psychedelic amphetamine, methylenedioxymeth-amphetamine. J Pharm Exp Ther 1987; 240:1-7.
6. Commins DL, Axt KJ, Vosmer G, Seiden LS. Endogenously produced 5,6-hydroxytryptamine may mediate the neurotoxic effects of parachloroamphetamine. Brain Res 1987;419:253-261.
7. O'Hearn G, Battaglia G, DeSouza EB, Kuhar MJ, Molliver ME. Methylenedioxymethamphetamine (MDMA) and methylenedioxymethamphetamine (MDMA) cause ablation of serotonergic terminals in forebrain: immunocytochemical evidence. J Neurosci 1988;8:2788-2803.
8. Ricaurte GA, DeLanney LE, Irwin I, Langston JW. Toxic effects of 3,4-methylenedioxymeth-amphetamine (MDMA) on central serotonergic neurons in the primate: importance of route and frequency of drug administration. Brain Res 1988; 446:165-168.
9. Ricaurte GA, Forno LS, Wilson MA, et al. MDMA selectively damages central serotonergic neurons in nonhuman primates. JAMA 1988;260:51-55.
10. Steele T, McCann UD, Ricaurte GA. 3,4-Methylenedioxymethamphetamine (MDMA, "Ecstasy"): pharmacology and toxicology in animals and humans. Addiction 1994;89:539-551.
11. McCann UD, Ricaurte GA. Lasting neuropsychiatric sequelae of (±) methlylenedioxymeth-amphetamine (Ecstasy) in recreational users. J Clin Psychopharmacol 1991;11:302-305.
12. Mordenti J, Chappell W. The use of interspecies scaling in toxicokinetics. In: Yacobi A, Kelly J, Batra V, eds. Toxicokinetics in new drug development. New York: Pergamon Press, 1989:42-96.
13. Ricaurte GA, Sabol KE, Seiden LS. Functional consequences of toxic amphetamine analog exposure. In: Cho A, Segal D, eds. Amphetamine and its analogs: neuropsychopharmacology, toxicology, and abuse. New York: Academic Press, 1994: 297-309.
14. McEntee WJ, Crook TH. Serotonin, memory, and the aging brain. Psychopharmacology 1991;103:143-149.
15. Altman HJ, Normile HJ. What is the nature of the role of the serotonergic nervous system in learning and memory: prospects for development of an effective treatment strategy for senile dementia. Neurobiol Aging 1988;9:627-638.
16. Hunter AJ. Serotonergic involvement in learning and memory. Biochem Soc Trans 1988;17:79-81.
17. Squire LR. Neural organization and behavior. In: Plum F, ed. Handbook of physiology. Vol. 5. Washington, DC: American Physiological Society, 1987:295-371.
18. McCann UD, Ridenour A, Shaham Y, Ricaurte GA. Serotonin neurotoxicity after (±)3,4-methylenedioxymethamphetamine (MDMA; "Ecstasy"): a controlled study in humans. Neuropsychopharmacology 1994;10(2):129-138.
19. Krystal JH, Price LH, Opsahl C, Ricaurte GA, Heninger GR. Chronic 3,4-methylenedioxy-methamphetamine (MDMA) use: effects on mood and neuropsychological function. Am J Drug Alcohol Abuse 1992;18:331-341.
20. Parrot AC, Lees A, Garnham NJ, Jones M, Wesnes K. Cognitive performance in recreational users of MDMA or Ecstasy: evidence for memory deficits. J Psychopharmacol 1998; in press.
21. Curran HV, Travill RA. Mood and cognitive effects of ±3,4-methylenedioxymethamphetamine (MDMA, "Ecstasy"): week-end "high" followed by mid-week low. Addiction 1997;92:821-831.
22. Linnoila M, Virkkunen M, Scheinin M, Nautila A, Rimon R, Goodwin FK. Low cerebrospinal fluid 5-hydroxyindoleacetic acid concentrations differentiates impulsive from nonimpulsive violent behavior. Life Sci 1983;33:2609-2614.
23. Roy A, Adinoff B, Linnoila M. Acting out hostility in normal volunteers: negative correlation with levels of 5-HIAA in cerebrospinal fluid. Psychiatry Res 1988;24:187-194.
24. Ricaurte GA, DeLanney LE, Wiener SG, Irwin I, Langston JW. 5-Hydroxyindoleacetic acid in cerebrospinal fluid reflects serotonergic damage induced by 3,4-methylenedioxymethamphetamine in CNS of nonhuman primates. Brain Res 1988;474:359-363.
25. Cho KC, Kumagai Y. Metabolism of amphetamine and other arylisopropylamines. In: Cho AK, Segal DS, eds. Amphetamine and its analogs: psychopharmacology, toxicology, and abuse. New York: Academic Press, 1994:43-77.
26. Wechsler D. Wechsler Memory Scale-Revised (WMS-R). New York: The Psychological Corporation, 1987.
27. Rey A. L'examen clinique en psychologie. Paris: Presses Universitaires de France, 1964.
28. Rey A. L'examen psychologique dans les cas d'encephalopathie traumatique. Arch Psychol 1941;28:286-340.
29. Osterrieth PA. Le test de copie d'une figure complex: contribution a l'etude de la perception et de la memoire. Arch Psychol 1944;30:286-356.
30. Wechsler D. Wechsler Adult Intelligence Scale-Revised (WAIS-R). New York: The Psychological Corporation, 1981.
31. Bolla KI, Schwartz BS, Stewart W, Rignani J, Agnew J, Ford DP. A comparison of neurobehavioral function in workers exposed to solvents. Am J Industr Med 1995;27(2):231-246.
32. Bolla-Wilson K, Bleecker ML. The influence of verbal intelligence, sex, age, and education on the Rey Auditory Verbal Learning Test. Dev Neuropsychol 1986;2(3):203-211.
33. Lezak MD. Neuropsychological assessment. New York: Oxford University Press, 1995.
34. Bleecker ML, Bolla KI, Agnew J, Ford DP, Schwartz BS, Powell S. Dose-related subclinical neurobehavioral effects of chronic exposure to low levels of organic solvents. Am J Industr Med 1991;19:715-728.
35. Dixon WJ, ed. BMDP statistical software manual. Berkeley, CA: University of California Press, 1992.
36. Sabel BA. Unrecognized potential of surviving neurons: within systems plasticity, recovery of function, and the hypothesis of minimal residual structure. Neuroscientist 1997;3: 366-370.
37. Bolla KI, Briefel G, Spector D, et al. Neurocognitive effects of aluminum. Arch Neurol 1992;49:1021-1026.
38. Satz P. Brain reserve capacity on symptom onset after brain injury: a formulation and review of evidence for threshold theory. Neuropsychology 1993;7:272-295.
39. Stumpf H, Jackson DN. Gender-related differences in cognitive abilities: evidence from medical school admissions testing program. Person Individ Differences 1994;17:335-344.
40. Esposito G, Van Horn JD, Wienberger DR, Berman KF. Gender differences in cerebral blood flow as a function of cognitive state with PET. J Nucl Med 1996;37:559-564.
41. Azari NP, Pettigrew ND, Pietrini P, Murphy DG, Horwitz B, Schapiro MB. Gender differences in patterns of hemispheric cerebral metabolism: a multiple regression/discriminant analysis of positron emission tomographic data. Int J Neurosci 1995;81:1-20.
42. Matthew RJ, Wilson WH, Tant SR. Determinants of resting regional cerebral blood flow in normal subjects. Biol Psychiatry 1986;21:907-914.
43. Kawas C, Resnick S, Morrison A, et al. A prospective study of estrogen replacement therapy and risk of developing Alzheimer's disease: The Baltimore Longitudinal Study of Aging. Neurology 1997;48:1517-1521.